Samil PharmaceuticalLtd Future Growth

Future criteria checks 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Samil PharmaceuticalLtd zu prognostizieren.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	43.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Samil PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A000520 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	196,346	1,664	-12,590	11,746	N/A
9/30/2023	189,293	2,600	-18,707	-43,369	N/A
6/30/2023	183,060	1,336	-28,155	-12,562	N/A
3/31/2023	179,566	343	-33,560	3,887	N/A
12/31/2022	179,676	-28	-44,502	4,154	N/A
9/30/2022	170,510	-4,989	-53,802	41,099	N/A
6/30/2022	158,910	-4,740	-40,593	15,161	N/A
3/31/2022	147,877	-5,619	-34,933	1,437	N/A
12/31/2021	134,247	-5,347	-31,194	1,417	N/A
9/30/2021	129,974	-2,761	-24,913	-1,229	N/A
6/30/2021	127,287	-1,327	-20,164	119	N/A
3/31/2021	122,793	132	-20,038	4,736	N/A
12/31/2020	122,999	1,341	-9,436	7,775	N/A
9/30/2020	123,114	940	2,747	15,430	N/A
6/30/2020	122,308	729	-9,557	11,450	N/A
3/31/2020	123,102	1,429	2,486	16,455	N/A
12/31/2019	121,107	786	-3,729	10,590	N/A
9/30/2019	114,364	-1,251	-13,267	40	N/A
6/30/2019	107,856	-3,368	-5	4,677	N/A
3/31/2019	102,805	-6,461	-7,234	-2,305	N/A
12/31/2018	94,600	-8,563	-6,538	-2,622	N/A
9/30/2018	96,882	-5,165	-2,899	1,319	N/A
6/30/2018	94,916	-4,605	-3,035	2,217	N/A
3/31/2018	92,286	-2,797	-40,013	3,258	N/A
12/31/2017	92,038	-1,267	-39,393	3,791	N/A
9/30/2017	90,658	-1,434	N/A	-680	N/A
6/30/2017	92,118	898	N/A	1,539	N/A
3/31/2017	94,685	948	N/A	5,206	N/A
12/31/2016	96,758	887	N/A	5,634	N/A
9/30/2016	94,010	306	N/A	9,953	N/A
6/30/2016	92,625	140	N/A	5,840	N/A
3/31/2016	88,656	553	N/A	1,357	N/A
12/31/2015	88,136	588	N/A	2,920	N/A
9/30/2015	85,795	-2,986	N/A	-1,492	N/A
6/30/2015	85,439	-6,170	N/A	-4,921	N/A
3/31/2015	85,849	-10,179	N/A	-11,314	N/A
12/31/2014	85,461	-11,190	N/A	-11,923	N/A
9/30/2014	87,683	1,148	N/A	-12,731	N/A
6/30/2014	87,545	3,601	N/A	-6,621	N/A
3/31/2014	89,207	7,191	N/A	-586	N/A
12/31/2013	89,229	7,930	N/A	-3,990	N/A
9/30/2013	89,993	-2,029	N/A	-6,076	N/A
6/30/2013	91,235	-1,321	N/A	-6,909	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von A000520 über der Sparquote liegt (2.3%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von A000520 schneller wachsen werden als der Markt KR

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von A000520 in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von A000520 schneller wachsen werden als der Markt von KR.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von A000520 schneller wachsen werden als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von A000520 in 3 Jahren voraussichtlich hoch sein wird

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Samil PharmaceuticalLtd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: ₩116 (vs ₩2.00 loss in FY 2022)

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 24%

New minor risk - Shareholder dilution

First quarter 2023 earnings released: EPS: ₩55.00 (vs ₩27.00 in 1Q 2022)

Full year 2022 earnings released: ₩2.00 loss per share (vs ₩425 loss in FY 2021)

Upcoming dividend of ₩80.00 per share

Samil Pharmaceutical Co.,Ltd announced that it has received KRW 4 billion in funding

Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 5 billion in funding

First quarter 2022 earnings released: EPS: ₩27.00 (vs ₩49.00 in 1Q 2021)

Upcoming dividend of ₩75.00 per share

Samil Pharmaceutical Co.,Ltd announced that it has received KRW 35 billion in funding from a group of investors

Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 35 billion in funding from a group of investors

Samil Pharmaceutical Co.,Ltd (KOSE:A000520) announces an Equity Buyback for KRW 500 million worth of its shares.

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS ₩219 (vs ₩129 in FY 2019)

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Samil Pharmaceutical Co.,Ltd, Annual General Meeting, Mar 19, 2021

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

New 90-day low: ₩19,950

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

New 90-day low: ₩20,050

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Upcoming Dividend of ₩150 Per Share

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

New 90-day low: ₩20,300

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Third quarter 2020 earnings released: ₩39.00 loss per share

New 90-day high - ₩24,400

New 90-day high - ₩23,650

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies